Posts filed under ‘GUIDELINES’

Antimicrobial prophylaxis in caesarean section delivery.

Exp Ther Med. August 2016 V.12 N.2 P.961-964.

Liu R1, Lin L1, Wang D1.

Author information

1 Department of Obstetrics, People’s Hospital of Linyi, Linyi, Shandong 276000, P.R. China.


Antimicrobial prophylaxis is used routinely for pre-, intra- and post-operative caesarean section.

One of the most important risk factors for postpartum infection is caesarean delivery.

Caesarean section shows a higher incidence of infection than vaginal delivery.

It is complicated by surgical site infections, endometritis or urinary tract infection.

The aim of the present study was to assess the usage of antimicrobials in women undergoing caesarean section at a Tertiary Care Hospital.

A prospective study was conducted in 100 women during the period of February 2013 to August 2013 in the inpatient Department of Gynaecology and Obstetrics.

Data collected included the age of the patient, gravidity, and type of caesarean section, which was analyzed for the nature and number of antimicrobials prescribed, duration of treatment, polypharmacy, fixed-dose combinations, generic/brand names used and failure of prophylaxis. Antimicrobial prophylaxis was administered to the patients.

The most commonly prescribed antimicrobial was a combination of ceftriaxone and sulbactam. Of 100 patients, 87% were aged 20-35 years.

The highest proportion of patients were primigravida 72%.

Elective procedure was carried out in 38%, the remaining were emergency C-section in whom intra- and post-operative antimicrobial prophylaxis was given for a duration of 7 days.

In total, 27% patients were reported with infection even after the antimicrobial prophylaxis. In conclusion, pre-operative prophylaxis was given in the early rupture of membranes.

Fixed-dose combinations were preferred. Incidence of infection even after antimicrobial prophylaxis was reported due to pre-existing infection, debilitating disease or prolonged rupture of membranes.

Patients with recurrent infection were shifted to amoxicillin and clavulinic acid combination. Drugs were prescribed only by brand names which is of concern.



February 9, 2018 at 1:16 pm

Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines

MMWR  January 26, 2018  V.67 N.3 P.103–108

Kathleen L. Dooling, MD1; Angela Guo, MPH1; Manisha Patel, MD1; Grace M. Lee, MD2; Kelly Moore, MD3; Edward A. Belongia, MD4; Rafael Harpaz, MD1


On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01B), was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged ≥50 years.

The vaccine consists of 2 doses (0.5 mL each), administered intramuscularly, 2–6 months apart (1).

On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥50 years…..


January 26, 2018 at 8:42 am

2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea

Clinical Infectious Diseases November, 29  2017  V.65  N.12 P.1963–1973


Andi L Shane; Rajal K Mody; John A Crump; Phillip I Tarr; Theodore S Steiner …

These guidelines are intended for use by healthcare professionals who care for children and adults with suspected or confirmed infectious diarrhea. They are not intended to replace physician judgement regarding specific patients or clinical or public health situations. This document does not provide detailed recommendations on infection prevention and control aspects related to infectious diarrhea.


PDF (hacer CLIC en PDF)

January 9, 2018 at 7:59 am

International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT).

Eur Respir J. September 10, 2017 V.50 N.3.

Torres A1,2, Niederman MS3,2, Chastre J4, Ewig S5, Fernandez-Vandellos P6, Hanberger H7, Kollef M8, Li Bassi G9, Luna CM10, Martin-Loeches I11, Paiva JA12, Read RC13, Rigau D14, Timsit JF15, Welte T16, Wunderink R17.

Author information

1 Dept of Pulmonology, Hospital Clínic de Barcelona, Universitat de Barcelona and IDIBAPS, CIBERES, Barcelona, Spain

2 These two authors contributed equally to this work.

3 Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, NY, USA.

4 Réanimation Médicale, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

5 CAPNETZ Stiftung and Thorax Centre in the Ruhr Area, Dept of Respiratory Medicine and Infectious Diseases, Evangelic Hospital in Herne and Augusta Hospital in Bochum, Bochum, Germany.

6 IDIBAPS, CIBERES, Barcelona, Spain.

7 Dept of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.

8 Pulmonary and Critical Care Division, Washington University School of Medicine, St Louis, MO, USA.

9 Dept of Pulmonology, Hospital Clínic de Barcelona, Universitat de Barcelona and IDIBAPS, CIBERES, Barcelona, Spain.

10 Hospital de Clínicas “José de San Martin”, Universidad de Buenos Aires, Ciudad de Buenos Aires, Argentina.

11 Dept of Clinical Medicine, Wellcome Trust – HRB Clinical Research Facility, St James’s Hospital, Trinity College, Dublin, Ireland and CIBERES, Barcelona, Spain.

12 Emergency and Intensive Care Dept, Centro Hospitalar São João EPE and Dept of Medicine, University of Porto Medical School, Porto, Portugal.

13 Academic Unit of Clinical Experimental Sciences and NIHR Southampton Biomedical Research Unit, Faculty of Medicine, and Institute for Life Sciences, University of Southampton, Southampton, UK.

14 Iberoamerican Cochrane Centre, Barcelona, Spain.

15 IAME, INSERM UMR 1137, Medical and Infectious Diseases Intensive Care Unit, Paris Diderot University and Bichat Hospital, Paris, France.

16 Dept of Respiratory Medicine, Medizinische Hoschschule Hannover, Hannover and German Centre of Lung Research (DZL), Germany.

17 Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.


The most recent European guidelines and task force reports on hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) were published almost 10 years ago.

Since then, further randomised clinical trials of HAP and VAP have been conducted and new information has become available. Studies of epidemiology, diagnosis, empiric treatment, response to treatment, new antibiotics or new forms of antibiotic administration and disease prevention have changed old paradigms.

In addition, important differences between approaches in Europe and the USA have become apparent.

The European Respiratory Society launched a project to develop new international guidelines for HAP and VAP.

Other European societies, including the European Society of Intensive Care Medicine and the European Society of Clinical Microbiology and Infectious Diseases, were invited to participate and appointed their representatives.

The Latin American Thoracic Association was also invited.A total of 15 experts and two methodologists made up the panel. Three experts from the USA were also invited (Michael S. Niederman, Marin Kollef and Richard Wunderink).

Applying the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methodology, the panel selected seven PICO (population-intervention-comparison-outcome) questions that generated a series of recommendations for HAP/VAP diagnosis, treatment and prevention.



November 22, 2017 at 12:00 pm

ESCMID guideline: diagnosis and treatment of acute bacterial meningitis.

Clin Microbiol Infect. 2016 May;22 Suppl 3:S37-62.

van de Beek D1, Cabellos C2, Dzupova O3, Esposito S4, Klein M5, Kloek AT1, Leib SL6, Mourvillier B7, Ostergaard C8, Pagliano P9, Pfister HW5, Read RC10, Sipahi OR11, Brouwer MC12; ESCMID Study Group for Infections of the Brain (ESGIB).

Author information

1 Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands.

2 Department of Infectious Diseases, Hospital Universitari de Bellvitge, Barcelona, Spain.

3 Department of Infectious Diseases, Charles University, Third Faculty of Medicine, Prague, Czech Republic.

4 Pediatric Highly Intensive Care Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.

5 Department of Neurology, Klinikum Großhadern, Munich, Germany.

6 Institute for Infectious Diseases, University of Bern, Bern, Switzerland.

7 Department of Intensive Care Medicine, Groupe Hospitalier Bichat-Claude Bernard, Paris, France.

8 Department of Clinical Microbiology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.

9 Department of Infectious Diseases, “D. Cotugno” Hospital, Naples, Italy.

10 Department of Infectious Diseases, Southampton General Hospital, Southampton, United Kingdom.

11 Department of Infectious Diseases and Clinical Microbiology, Ege University, Izmir, Turkey.

12 Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands. Electronic address:



November 22, 2017 at 11:58 am

2007 LEGIONELLA and the Prevention of LEGIONELLOSIS – WHO MANUAL 276 pags

World Health Organization 2007

Edited by:

Jamie Bartram, Yves Chartier, John V Lee,

Kathy Pond and Susanne Surman-Lee


November 20, 2017 at 11:31 am

LEPTOSPIROSIS – Guia para el Equipo de Salud – Ministerio Salud de la Nación Argentina


Guia para el Equipo de Salud – Ministerio Salud de la Nación Argentina

Abril 2014

  1. Introducción
  2. Manifestaciones clínicas
  3. ¿Cuándo sospechar leptospirosis?
  4. ¿Cómo confirmar leptospirosis?
  5. ¿Cómo notificar el caso de leptospirosis?
  6. ¿Cómo se trata el paciente con leptospirosis?
  7. Flujograma de manejo de casos sospechosos de leptospirosis
  8. Diagnóstico diferencial
  9. ¿Qué hacer si se confirma?
  10. ¿Cómo se tratan los casos caninos de leptospirosis?
  11. Prevención de la leptospirosis en la familia y la comunidad


November 18, 2017 at 10:05 am

Older Posts


February 2018
« Jan    

Posts by Month

Posts by Category